S-1/A: Nexalin Technology Files Amendment No. 2 to Form S-1 for Resale of Common Stock

Nexalin Technology is filing an amendment to its Form S-1 registration statement to allow selling stockholders to resell up to 2,798,613 shares of common stock.

Summary

• Nexalin Technology, Inc. has filed Amendment No. 2 to its Form S-1 registration statement with the SEC.
• The amendment covers the resale of up to 2,798,613 shares of the company's common stock by selling stockholders.
• These shares include those issuable upon exercise of warrants issued to Maxim Partners, LLC and purchasers of units in the company's 2022 public offering, as well as shares issued to Maxim Partners for a renewal of their engagement agreement.
• The company will not receive any proceeds from the resale of these shares, but may receive proceeds if the warrants are exercised for cash.
• The selling stockholders may sell the shares through public or private transactions at prevailing market prices or negotiated prices.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol NXL, with a last reported sale price of $2.60 per share on January 29, 2025.
• Nexalin is an emerging growth company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: Neutral sentiment as this is a standard filing for resale of shares. The company's prospects are not directly impacted, but the potential for dilution and price volatility exists.

Positives

• The registration allows selling stockholders to offer their shares for resale, potentially increasing liquidity.
• If warrants are exercised for cash, Nexalin will receive proceeds that can be used for working capital, capital expenditures, and product development.

Negatives

• The company will not receive any proceeds from the resale of the shares by the selling stockholders.
• The selling stockholders may choose to sell the shares at prices below the current market price, which could adversely affect the market price of the common stock.
• A large number of shares of common stock may be sold in the market following this offering, which may significantly depress the market price of the common stock.

Risks

• The selling stockholders may sell shares at prices below the current market price.
• A large number of shares being sold could depress the market price of the common stock.
• The company's stock price may be volatile.
• The company may not be able to comply with Nasdaq's continued listing requirements.
• The company has identified certain material weaknesses in its internal controls, which could impair its ability to produce accurate consolidated financial statements on a timely basis.

Future Outlook

The selling stockholders may sell any, all, or none of the shares of common stock covered by this prospectus, and the company does not know when or in what amount the selling stockholders may sell their shares.

Industry Context

This filing is a standard procedure for companies that have previously issued securities and are allowing their investors to resell those securities in the public market. It does not necessarily reflect a change in the company's business or prospects.

Stakeholder Impact

• Existing shareholders may experience dilution if warrants are exercised.
• The market price of the common stock could be affected by sales from selling stockholders.

Next Steps

• Selling stockholders may offer or sell shares from time to time.
• The company will monitor the exercise of warrants and use any proceeds for working capital and general corporate purposes.

Key Dates

Keywords

common stock, resale, warrants, selling stockholders, registration statement, Nexalin Technology, NXL, Maxim Partners, public offering, shares